This review highlights current interventional clinical trials for HIV-associated malignancies (HIVAMs), with emphasis on 4 mechanistic areas: immunomodulatory therapies and gene therapies, including immune checkpoint inhibitors; cytotoxic therapies; novel tumor-targeted and virally targeted therapies in both AIDS-defining and non-AIDS-defining cancers (NADC); and other screening or topical/ablative interventions. A search on ClinicalTrials.gov located 35 trials, including 12 immunomodulatory or gene therapy trials, 6 cytotoxic therapy trials, 10 trials of therapies with tumor or viral molecular targets, and 7 trials evaluating screening interventions or topical or ablative therapies. Study drugs, mechanisms, and outcomes of interest, including future directions, are discussed. Targeted therapies and immunotherapies address not only the tumor but underlying viral oncogens, including possible benefits on HIV-specific immunologic control. The resulting science from the trials listed in this review will provide important translational breakthroughs for people living with HIV (PLWH) and cancer. We highlight disease-specific challenges that could be addressed in future studies, including testing the safety and efficacy of cuttingedge immunotherapy and targeted treatments used in the general cancer population, and improving gaps in knowledge and practice for cancer screening and its treatment, especially in low-resource regions. Additional important considerations include identification of novel therapies for virally mediated tumors that disproportionally present in PLWH, how to treat persons with HIVAM and advanced immunosuppression, and how to comanage both diseases in antiretroviral therapy-naïve persons and those receiving care in settings where supportive therapies for hematologic toxicities and infections are limited. Current and future clinical trials should address needs of both resourcereplete and -limited regions, as well as cancers that are uncommon in or respond differently to HIV-negative populations (eg, Kaposi sarcoma or anal cancer), in addition to an increased focus on NADCs not traditionally linked with HIV, such as lung or gastrointestinal tumors.
Since the advent of combination antiretroviral therapy (ART), malignancies have become among the leading causes of death in persons living with HIV (PLWH). 1 As treatment outcomes for PLWH and malignancies have improved in the past 2 decades, clinical trials for HIV-associated malignancies (HIVAMs) have also tremendously evolved. Until recently, most cancerspecific treatment trials excluded PLWH. For example, the Friends of Cancer Research HIV Working Group reviewed eligibility criteria from studies supporting 46 new drug applications of agents in patients with cancer a University of Washington, and Study of ART use with HIVAM treatment is particularly important, because the WHO only recently began to strongly recommend initiating ART for all PLWH regardless of CD4-positive T-cell count (CD4 count) after 2 large randomized trials demonstrated overall benefit, especially in terms of non-AIDS-defining morbidity and mortality. [3] [4] [5] Further understanding of the role of chronic immune activation and exhaustion in both HIV and cancer has also supported the idea that ART and cancer-directed therapies must go hand-in-hand. [6] [7] [8] [9] Thus, in cancers common in non-HIV-infected populations, many trials have had to focus on safety and pharmacokinetic studies in persons on ART, simply to prove that the regimen can be tolerated immunologically and that these regimens do not cause drug-drug interactions with strong inducers or inhibitors of cytochrome P450 enzymes (eg, efavirenz or protease inhibitors, respectively).
In addition, the burden of cancer is now being seen in sub-Saharan Africa (SSA) and other resource-limited regions, where longer life expectancy on ART and higher burden of viral oncogens has caused HIVAMs to become the second-leading cause of death, after tuberculosis, in PLWH. Thus, current and future clinical trials will need to address the needs of both resource-replete and resource-limited areas, as well as cancers that are uncommon or respond differently in HIV-negative populations, such as Kaposi sarcoma (KS) or anal cancer. This review summarizes and highlights current HIVAM clinical trials, with emphasis on 4 mechanistic areas: immunomodulatory therapies and gene therapies, including immune checkpoint inhibitors (ICIs); cytotoxic therapies; novel tumor-targeted and virally targeted therapies in both AIDS-defining cancers (eg, KS, AIDS-defining lymphomas, and cervical cancer) and non-AIDS-defining cancers (NADCs); and other screening or topical/ablative interventions.
Process
We initiated a search on ClinicalTrials.gov using the following search terms: "HIV" or "AIDS" or "acquired immunodeficiency syndrome" plus "malignancy," "cancer," "squamous intraepithelial lesions," or "Kaposi sarcoma." We limited trials to interventional treatment and screening trials, and included only those listed as active, recruiting, enrolling, or not yet recruiting. A total of 35 trials were found, including 12 immunomodulatory or gene therapy trials, 6 cytotoxic therapy trials, 10 trials of therapies with tumor or viral molecular targets, and 7 trials evaluating screening interventions or topical or ablative therapies.
ICIs, Gene Therapy, and Other Immunotherapies
Among the immunomodulatory or gene therapy trials, most were phase I or I/II (n=9; Table 1 ). Most of the trials focused on lymphoma (n=6), 2 on KS, 1 on non-small cell lung cancer, 1 on multiple tumor types, and 1 on human papillomavirus (HPV)-related cancers. There were only 3 phase II studies, all of which involved a PD-1 inhibitor alone or in combination with a CTLA-4 inhibitor. In addition, 5 of the lymphoma studies evaluated gene-modified stem cell trials with or without cytotoxic chemotherapy, with 1 phase I/II allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-cell transplant trial for EBV-associated lymphoproliferative disorders. Lastly, there were 2 studies of pomalidomide, a thalidomide analog and immunomodulatory drug (IMiD) that augments Tcell-and NK-cell-mediated immunity and exerts antiangiogenic and antineoplastic effects. 10 These trials evaluated pomalidomide in combination with liposomal doxorubicin for advanced or refractory KS, and pomalidomide alone in individuals with high-grade squamous intraepithelial lesions (HSIL).
Immunomodulatory Agents and Effects on HIV-1 Replication and Latency
Blocking of both PD-1 and CTLA-4 in HIV-1-specific, CD4-and CD8-positive T cells leads to a recovery of cell proliferation and cytokine production in vitro. 11 Furthermore, CTLA-4 blockade also increases CD4-positive T-cell proliferation and augments HIV-specific CD4-positive T-cell function. 12, 13 In a simian immunodeficiency virus (SIV)-infected macaque model, blockade of PD-1 by a monoclonal antibody increased the number of virus-specific CD4-positive T cells and memory B cells and levels of envelope-specific antibodies. These immunologic effects were associated with the lack of side effects and significantly increased overall survival of the treated SIV-infected macaques.
14 Given these promising data, several ICI trials, including the AMC-095 study of combined CLTA-4/PD-1 blockade, featured laboratory end points, in- cluding quantitation of the replication-competent viral reservoir in peripheral blood mononuclear cells, and measurement of anti-HIV-specific T cells. The French ANRS CO24 OncoVIHAC cohort will prospectively follow all available PLWH who receive ICIs as part of routine cancer care to evaluate their safety and effects on the HIV reservoir (ClinicalTrials.gov identifier: NCT03354936). The Cancer Immunotherapy Trials Network (CITN) trial of pembrolizumab in solid tumors and Hodgkin lymphoma will also address these questions through longitudinal analysis of the replication-competent HIV reservoir (ClinicalTrials.gov identifier: NCT02595866).
Hematopoietic Cell Transplant and Gene Therapy Trials
Current allogeneic and autologous hematopoietic cell transplant (HCT) trials focus on safely increasing the aggressiveness of conditioning regimens, as well as leveraging clinical indications for autologous HCT to investigate gene therapies for functional HIV cure. City of Hope is currently testing the safety and impact of high-dose conditioning with carmustine, etoposide, and cyclophosphamide followed by autologous HCT on HIV-specific immune reconstitution in patients with HIV-associated lymphoma (NCT02337985). Preliminary results of the CTN 0903/AMC-080 trial showed that overall survival in myeloablative/nonablative transplant recipients with HIV was similar to historical results for non-HIV-infected persons (82% at 6 months, 57% at 1 year), with no deaths attributable to HIV. 15 Another ongoing study is evaluating the feasibility and efficacy of subcutaneous enfuvirtide monotherapy as a bridge for patients who are unable to take oral ART following HCT (ClinicalTrials.gov identifier: NCT01836068).
Several active trials leverage clinically indicated HCT to test gene-edited autologous hematopoietic cells targeted at HIV. Each study is using a lentivirus vector with 3 gene targets in different combinations. AMC-097 is evaluating transduced autologous CD34-positive cells with short hairpin RNA (shRNA) CCR5 that causes interference to transcription of this gene, preventing expression of one crucial coreceptor required for HIV-1 cell entry. TRIM5a prevents proviral integration by blocking uncoating of HIV capsids in the cytosol, which is thought to be one of the factors that render rhesus monkeys resistant to HIV infection.
The last component is a TAR decoy oligonucleotide, which outcompetes HIV Tat to prevent transcription at the promoter. 16 The study from Fred Hutchinson Cancer Research Center (NCT02343666 ; Table 1 ) pairs a mutated CCR5 sequence with an HIV entry inhibitor (C46) and a chemoselection agent (P140K). P140K causes cellular resistance to O6-benzylguanine, a highly toxic suicide inhibitor, thus enriching the population of transduced cells while depressing both nontransformed HCT and malignant cell lines. The last study tests a rHIV7-shI-TAR-CCR5RZ combination, again targeting TAR and CCR5, this time through a ribozyme that catalyzes CCR5, added to a different shRNA (rHIV7), which blocks transcription of HIV Tat/Rev (NCT02337985).
Cytotoxic Chemotherapy
Of the 6 trials evaluating novel cytotoxic therapeutic trials, 5 are accruing PLWH with Hodgkin's or nonHodgkin lymphomas (Table 2 ). Early findings from the only phase I/II safety and efficacy trial evaluating substitution of the CD30 monoclonal antibody brentuximab vedotin for bleomycin has demonstrated safety in 7 patients. 17 Other studies evaluating cytotoxic therapy are phase II studies determining the safety and efficacy of other novel therapies for HIV-associated lymphoma, including short-course EPOCH (etoposide/prednisone/vincristine/cyclophosphamide/doxorubicin) and the addition of ibrutinib in dose-adjusted EPOCH as frontline treatment (NCT00006436 and NCT03220022, respectively). One trial is evaluating the safety and efficacy of rituximab plus CHOP (prednisone/vincristine/cyclophosphamide/ doxorubicin) in Malawi, a resource-limited setting (NCT02660710), and another is determining the efficacy of methotrexate/leucovorin/rituximab in primary central nervous system lymphoma (NCT00267865).
The only currently open phase III trial in this group is evaluating the novel modulated electrohyperthermia (mEHT; Oncothermia) plus standard chemoradiotherapy for locally advanced cervical cancer in South Africa (NCT03332069). Previous studies have shown that the addition of hyperthermia to conventional cytotoxic therapy improves treatment efficacy. 18 mEHT utilizes the principles of extracellular hyperthermia using low frequency modulated direct electroic field, but not temperature-dependent, effects of electromagnetic fields and special modulation, the effect of which may exceed that of the overall heating (macroscopic temperature elevation) by 3-to 4-fold. 19 mEHT does not require hyperthermia-range temperature and may be performed safely, without invasive thermal control.
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Targeted and Molecular Therapies
We identified 10 active trials of therapies targeted at viral oncogenes or other molecular targets, most of which are phase I or II (Table 3) . Four trials include antiviral drugs for KS-associated herpesvirus (KSHV) activity in KS or KSHV-associated lymphoproliferative disorders. An NCI-sponsored study is evaluating 5 different oncolytic virotherapy approaches to multicentric Castleman's disease and/or KSHV-associated inflammatory cytokine syndrome (KICS), including combinations of zidovudine and ganciclovir, IMiDs, sirolimus, rituximab, and interferon-a, with or without cytotoxic chemotherapy per underlying disease (NCT00092222). AMC-098 is studying nelfinavir, an early-generation HIV protease inhibitor once abandoned for its off-target effects, and more recently found to directly inhibit KSHV replication in vitro and in vivo (NCT03077451). [21] [22] [23] This trial uses higher-thanstandard nelfinavir dosing to parlay the well-known "off-target" effects on NFκ, VEGF, HIF-1-α, and PI3K/ Akt pathways. A Mexican government-sponsored study is evaluating the impact of 4 weeks of valganciclovir on KICS in ART-and treatment-naïve persons with limited KS (NCT03296553). Finally, a Brazilian study is evaluating the safety and maximum tolerated dose of using a class I histone deacetylase inhibitor (HDAC) "kick" followed by valganciclovir to "kill" latently infected KSHV-infected cells (NCT03397706). Three additional KS trials target tumor angiogenesis. The first (AMC-096) uses recombinant soluble Ephrin B4 fusion protein (sEphB4-HSA) inhibition of the EphB2-VEGF pathway (NCT02799485). The second study is from the United Kingdom evaluating the safety and tolerability of selumetinib, an orally active, ATP-independent inhibitor of the mitogenactivated protein kinase kinase (MEK/ERK 1/2) pathway (NCT01752569). The third study (AMC-087) is a multitumor phase I dose-finding study evaluating the safety of the c-MET/multi-tyrosine kinase inhibitor cabozantinib in PLWH, including patients with KS and several other cancers (NCT01822522).
Finally, 3 studies are evaluating antiviral approaches for HPV-related neoplasia. The first is an open-label phase I trial to determine the safety and tolerability of an acyclic nucleoside phosphate with direct anti-HPV activity for HSIL of the anal canal (NCT03202992). The others are phase III/IV randomized controlled trials evaluating the FDA-approved 9-valent Gardasil HPV vaccine as a therapeutic strategy, including one for preventing HSIL in women coinfected with HIV and high-risk HPV (COVENANT), and the other for preventing recurrence of HSIL after local ablative therapy for a first vulvar or anal HSIL lesion. 
Interventional Screening Practices and Topical Therapies
We found 7 trials evaluating screening and treatment practices, all of which are aimed at detecting or treating HPV-associated squamous cell tumors or precursor lesions of cervical, oropharyngeal, or anal cancer (Table 4) . One diagnostic trial in the cervix is evaluating the use of HPV screening plus either cytology or visual inspection with acetic acid for the detection of HSIL (NCT03324009). The second diagnostic test pairs carbon monoxide testing with a visual inspection of the oral cavity for malignancies and premalignancies and incorporates smoking cessation with patient follow-up (NCT02823847).
Of the remaining trials, 1 is evaluating the efficacy of topical curcumin in cervical HSIL (NCT02944578), and 4 are focusing on topical or ablative treatments of early invasive anal cancer or HSIL (Table 4) . There is no standard of care for treating anal dysplasia, although electrocautery or argon plasma coagulation are both common firstline treatments, and previously documented recurrence rates have ranged from 0% to 79%. AMC-A01 (ANCHOR; NCT02135419) is investigating whether multimodal treatment of HSIL reduces incidence of anal carcinoma compared with observation in PLWH. AMC-092 (NCT02437851) is evaluating the efficacy of surgical excisional treatment alone for superficially invasive squamous cell carcinoma, and AMC-088 (NCT02059499) is an ongoing randomized study of intra-anal imiquimod 2.5% versus topical 5-FU 5% versus observation for the treatment of anal HSIL in PLWH. Finally, a phase II study is evaluating the safety and efficacy of radiofrequency ablation for anal HSIL (NCT03302858).
Future Directions
There are a broad range of active and soon-to-be-activated trials for HIVAM. Increasingly, as is the case for oncology clinical trials in general, the focus is on immunotherapy and targeted therapy, with lesser emphasis on cytotoxic therapy alone. Although the resulting science from the trials discussed provide important translational breakthroughs for PLWH, the following disease-specific challenges need to be addressed in future studies.
Kaposi Sarcoma
Ongoing challenges in KS include suboptimal efficacy and attendant toxicities of cytotoxic chemotherapy, especially regions that bear the burden of this disease, such as SSA. Given the benefit of ICIs on reversing immune exhaustion, one of the key hypotheses being addressed is that these agents may have synergistic benefit for both HIV and herpesvirus infections, in contrast to other modalities that risk worsening virologic control. However, in addition to the risk of severe immunologic reactions, 24 cost and requirement for intravenous administration provide barriers to use of these therapies in lowresource settings. Additionally, given lower-thanexpected efficacy of targeted therapies, future KS trials could consider combining multiple, ideally orally available agents with different mechanisms to target redundant KSHV and tumor-promoted angiogenesis and cell survival pathways.
25-27
HPV-Related Malignancies
Limited prospective outcome studies are available in HIV-associated cervical cancer, and retrospective studies have demonstrated that PLWH have decreased tolerability to chemoradiotherapy (chemoRT) compared with persons without HIV. 28, 29 Hematologic toxicity, particularly, often results in dose reductions or elimination of concurrent chemotherapy during RT. Future planned studies will examine the toxicities of outback carboplatin/taxol in ART-treated PLWH for 4 cycles after standard chemoRT for locally advanced cervical cancer. In addition, nelfinavir inhibits the phospho-AKT pathway and decreases oxygen consumption. [30] [31] [32] As such, it has been investigated as a radiation sensitizer in a variety of cancers in HIV-negative patients. Compared with common radiation sensitizers, such as platins, potential benefits of nelfinavir include oral administration, relatively manageable side effects, and ease of delivery without refrigeration or handling precautions in low-resource regions.
Lymphoma
There are many new horizons, including gene therapy, for treatment of lymphoma in higher-resource settings. Most of these could and should include PLWH routinely, and may simultaneously be able to evaluate strategies for HIV cure concurrent with need for cancer treatments. However, with the burden of AIDS-related lymphoma in SSA, and no current standard-of-care in this setting, future trials should focus on moving care toward accepted standards for resourced settings, where HIV infection may no longer be an independent predictor or death, once risk score and receipt of rituximab are taken into account. 33 Establishing the safety of rituximab in PLWH has been important, as will be ensuring access to this drug, including in the United States, where it is less commonly offered to PLWH.
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NADCs and General Considerations
Most ongoing trials focus on cancers and precancers that are virally mediated and have a higher incidence among PLWH. Only a few phase I studies are investigating appropriate dosing and tolerability of agents among PLWH for NADC, such as anal, lung, hepatocellular, and oropharynx cancers. Future trials will need to determine the dosing and safety of novel cancer therapies for PLWH, as new therapies for cancers that are common in HIV-negative persons begin to be used to treat HIVAMs. This is of particular importance, given that PLWH have been shown to be less likely to receive cancer therapy 34 and to have poorer outcomes. 35 Additionally, increasing evidence shows that a robust immune system is critical to cancer control, as evidenced by improved outcomes with immunotherapy for multiple disease sites. [36] [37] [38] [39] Further work identifying and exploiting immunologic and molecular characteristics of cancers in PLWH may also improve treatment outcomes for PLWH.
Summary
Recently completed trials overall support the position by the Friends of Cancer Research HIV Working Group that, barring specific concerns, PLWH should be treated similar to individuals without HIV infection and should be included in similar trials and standard of care, assuming ART is carefully managed. 40 However, more research is needed to address several themes in HIVAM. Future trials should focus on not only testing safety and efficacy of cutting-edge immunotherapy and targeted treat-ments being used in the general cancer population, but also improving the gaps in knowledge and practice for cancer screening and treatment, especially in low-resource regions. Additional important considerations include identifying novel therapies for virally mediated tumors that disproportionally present in PLWH, treating persons with HIVAM and advanced immunosuppression, and optimizing comanagement of both diseases in ART-naïve persons and those receiving care in settings where supportive therapies for hematologic toxicities and infections are limited. 40 
